31 results about "Clinical pregnancy" patented technology

The present invention relates to the use of an oxytocin receptor antagonist in females undergoing embryo transfer as part of an assisted reproductive technology. In particular, methods are provided for increasing ongoing implantation rate, increasing ongoing pregnancy rate, increasing clinical pregnancy rate, and/or increasing live birth rate in a female subject undergoing embryo transfer. Specifically, the antagonists are released in the luteal phase when the endometrium is receptive for embryo implantation and/or when the embryo has reached the blastocyst-stage.

The invention relates to the field of genetic diagnosis and human assisted reproduction, and more particularly relates to an embryo pre-implantation genetic diagnosis technique (PGD). According to the method provided by the invention, for patients suffering from chromosomal balanced translocation (including reciprocal translocation and Robertson translocation) and mates thereof, family haplotype linkage analysis is performed on the chromosomes of the embryos obtained by in vitro fertilization and the relatives of the translocation carrier, the embryos with chromosomal balanced translocation and the embryos with normal chromosomes can be rapidly, simply and accurately distinguished, and at the same time, the chromosome copy number variation of the embryo is screened, so that the clinical pregnancy rate is improved, the genetic transmission of the chromosomal balanced translocation to the next generation is timely blocked before embryo implantation, and thus the development and progress of the human assisted reproductive technology are promoted to a certain extent.

The invention belongs to the technical field of assisted reproduction, and particularly relates to a oocyte in-vitro maturity nutrient solution and a preparation method thereof. The oocyte in vitro manturation culture medium is based on commercialized tissue nutrient solution TCM199, and accurately added commercialized constituents comprise 0.075-0.10 IU/ml FSH and 0.5-0.8 IU/ml HCG, 0.1-0.2 microgram/ml 17 beta-estradiol, and human commercialized replaced serum or human albumin with the volume percent being of 10-20 percent. The oocyte in-vitro maturity nutrient solution is stable in constituents and quality, can be industrially produced. By adding commercialized human replaced serum and serum albumin, improving the concentration of the estradiol, FSH and HCG in the culture medium and simulating in-vivo mature environment in human oocyte, a good clinical effect is obtained, the in vitro maturity rate of oocyte reaches 72.08 percent, and the clinical pregnancy rate reaches 23.71 percent.

The invention relates to a homogeneous immunoassay reagent kit for detecting beta human chorionic gonadotropin and a preparation method and application thereof. The homogeneous immunoassay reagent kitof the beta human chorionic gonadotropin obtained by the method provided by the invention has a wide range of signal values and reaches a quantitative test standard when used for analyzing in a photoexcited chemiluminescence immunoassay platform; the homogeneous immunoassay reagent kit is high in sensitivity and can be used for accurate in-vitro diagnosis of beta-hCG levels in serum or urine; thehomogeneous immunoassay reagent kit has good stability and high precision; and by analysis system optimizing (antibody dosage and buffer and the like), the analytical performance meets industry standards, and a reference is provided for clinical pregnancy diagnosis and dynamic monitoring of hydatidiform moles and therapeutic effect of chorio-epithelioma.

The invention discloses an auxiliary activation device for a frozen embryo, and relates to the technical field of medical equipment. The device comprises a shell internally provided with a containingcavity; the frozen embryo contained in a straw is arranged in the containing cavity; a light source is arranged on the inner wall surface of the shell; and the light source emits low-intensity light to the frozen embryo. The auxiliary activation device for the frozen embryo can be used as an auxiliary activation means for the frozen embryo, the survival rate of frozen embryo recovery is increased,and therefore the clinical pregnancy rate of frozen embryo recovery is increased.

An assisted reproductive technology library management system based on the Internet of Things comprises a reproductive center client, a supplier terminal and a logistics terminal which are connected together through the computer or mobile phone Internet of Things. According to the system, the system can be connected with a hospital information system, a supplier warehouse management system and a cold-chain logistics system, so that the quality of the embryo culture medium is controlled and supervised from all links, an important role is played in improving the embryo culture quality and the clinical pregnancy rate, and the system can be widely applied to all reproductive medical centers in China.

The invention provides a biomarker and a medicament for recurrent implantation failure. The biomarker comprises one or more of pathway related genes with the G0 annotation being GO: 0030286, GO: 0003777, GO: 0007018, GO: 0016887, GO: 0005874, GO: 0005858, GO: 0060285 and GO: 0005871, or/and the KEGG annotation being hsa05016, and one or more of pathway related genes with the G0 annotation being GO: 0030286, GO: 0003777, GO: 0007018, GO: 0016887, GO: 0005874, GO: 0005858, GO: 0060285 and GO: The biomarkers are used for characterizing, diagnosing or classifying'subclinical hypopituitary hypofunction 'patients with repeated implantation failure and predicting the therapeutic reactivity of the patients with repeated implantation failure to luteal support therapy; the invention also provides a medicament for repeated implantation failure, a lutein therapy medicament and a luteinizing activity related medicament, the lutein therapy medicament is a medicament for regulating estrogen and/or progestational hormone, and the luteinizing activity related medicament is a medicament for regulating the estrogen and/or progestational hormone after embryo implantation by applying human chorionic gonadotropin. The repeated implantation failure object has the characteristics that (1) clinical pregnancy is not observed in continuous three or more times of high-quality embryo transplantation, (2) the pathogenesis of RIF is indefinite, and (3) the blood luteinizing hormone level is less than or equal to 5IU/L on the second day (D2 day) after ovulation.

The invention discloses a Chinese herbal compound composition capable of treating anovulatory infertility and application thereof. The Chinese herbal compound composition is prepared from 1-12 parts of radix rehmanniae preparata, 1-10 parts of roasted rhizoma atractylodis macrocephalae, 1-7.5 parts of poria cocos, 1-6 parts of fructus corni, 1-6 parts of radix salviae miltiorrhizae, 1-9 parts of fructus rubi, 1-6 parts of rhizoma dioscoreae, 1-9 parts of radix glehniae, 1-6 parts of semen cuscutae, 1-7.5 parts of fructus rosae laevigatae and 1-6 parts of semen ziziphi spinosae. The Chinese herbal compound composition achieves a good treatment effect when applied to the clinical treatment of anovulatory infertility under the guidance of traditional Chinese medicine theory. Clinical observation results show that the Chinese herbal compound composition mostly promotes the ovulation of single dominant follicles, has little influence on the endometrium and makes endometrium development synchronized with follicle development, so that a high periodic ovulation rate and clinical pregnancy rate are obtained, and a good treatment effect on anovulatory infertility is achieved. Besides, the Chinese herbal compound composition is very low in toxic or side effect and safe and reliable in clinical medication.

The invention provides a traditional Chinese medicinal composition for treating hypothyroidism. The traditional Chinese medicinal composition is prepared from the following raw medicinal materials in parts by weight: 100-300 parts of stir-baked fructus gardeniae, 200-500 parts of oriental wormwood, 150-450 parts of prepared rehmannia root, 200-500 parts of raw rehmannia root, 150-450 parts of bighead atractylodes rhizome, 100-300 parts of mulberry leaf and 100-300 parts of lophatherum gracile. The traditional Chinese medicinal composition is supported by the solid classic theory of gynecology of traditional Chinese medicine, is reasonable in component composition and exact in curative effect, can be used for remarkably increasing the clinical pregnancy rate, does not have toxic or side effect, is safe to take and easy to control quality due to few medicinal materials at low cost, and can be applied to preparation of the traditional Chinese medicinal composition for treating sub-clinical hypothyroidism in in-vitro fertilization-embryo transplantation.

The invention relates to an application of a GM-CSF factor as a biomarker in screening assisted reproductive transplantation embryos and a method, the method takes the GM-CSF factor as the biomarker,and the concentration of the GM-CSF factor in a blastocyst culture solution of the embryos is in positive correlation with the transplantation success rate of the embryos. The successful transplantation means that the screened embryo can be pregnant after transplantation, and the pregnancy comprises HCG positive, clinical pregnancy and continuous pregnancy. The HCG positive is positive when a pregnancy marker HCG in serum or urine is detected in 11 days after transplantation. The clinical pregnancy refers to intrauterine pregnancy sacs found through vaginal ultrasound 30 days after transplantation, wherein the continuous pregnancy is that the pregnancy lasts for more than 3 months. The method can also be combined with morphological scoring, and the higher the concentration of the GM-CSF factor is, the higher the success rate of embryo transplantation with better morphological scoring quality is.

The invention relates to a sperm optimization device and a sperm optimization method used for horizontal intracytoplasmic single sperm injection. The sperm optimization device comprises a sperm optimization trough, the interior of the sperm optimization trough is divided into a sperm storage pool and a high-quality sperm pool by a clapboard, a sperm swimming channel is formed in the clapboard, thesperm swimming channel is communicated with the sperm storage pool and the high-quality sperm pool, and a constant temperature heating plate I and a constant temperature heating plate II are respectively arranged below the sperm storage pool and the high-quality sperm pool; according to the sperm optimization method, sperm with good activity swims from the sperm storage pool with low temperatureto the high-quality sperm pool with high temperature through the sperm swimming channel by utilizing the temperature difference between the sperm storage pool and the high-quality sperm pool. According to the invention, sperm obtain by a gradient centrifugation method can be further optimized, sperm with relatively good activity is selected, and the selected sperm is used for fertilization, so asto improve the fertilization rate of ICSI and the development ability of embryos after ICSI, and finally increase the clinical pregnancy rate.

The invention discloses a molecular marker miR-122. A nucleotide sequence of the molecular marker miR-122 is as shown in SEQ ID NO: 1. The invention also discloses a kit for male fertility diagnosis,a reagent for determining the expression quantity of the molecular marker miR-122 in seminal fluid, and a fertilization rate and a blastocyst formation rate are prompted through the expression quantity of the miR-122. By detecting the expression quantity of miR-122 in the seminal fluid, fertilization, embryonic development and clinical pregnancy conditions can be judged, a simple, convenient, easy-to-operate and high-sensitivity method is provided for male fertility judgment, and the method can be used as a new index for evaluating the male fertility.

The invention relates to the technical field of human assisted reproduction, in particular to a novel culture dish used for fertilization. The culture medium is a four-hole dish or an annular dish; a dish body of the culture dish comprises a bottom wall, a main side wall and an auxiliary side wall which are integrally formed; the main side wall and the auxiliary side wall are arranged on the bottom wall; the auxiliary side wall is positioned on an inner side of the main side wall; in the four-hole dish, a hole is formed in each of four corners on an inner side of the auxiliary side wall; in the annular dish, a middle hole is formed in the middle of the auxiliary side wall. Sperms added during fertilization are separated from an ovum by utilizing a bionic principle and good-quality sperms are enabled to swim to the periphery of the ovum for fertilization by utilizing a groove, so that the good-quality embryo rate and the clinical pregnancy rate of in-vitro fertilization can be increased.

The invention relates to a method for identifying a CNV microdeletion and microduplication syndrome diseased embryo and a normal embryo. The invention belongs to the field of genetic diagnosis and human assisted reproduction, and more particularly relates to a pre-implantation embryo detection technology (PGT). According to the method disclosed by the invention, family haplotype linkage analysis is carried out on a patient suffering from the CNV microdeletion and microduplication syndrome, a partner of the patient, an embryo after in-vitro insemination and chromosomes of relatives of the patient or fetal tissues suffering from the CNV microdeletion and microduplication syndrome; the method can quickly, simply, conveniently and accurately distinguish the diseased embryo carrying CNV from the normal embryo, and simultaneously screen the chromosome aneuploid of the embryo, thereby improving the clinical pregnancy rate, realizing the timely detection of the diseased embryo and the transplanted non-diseased embryo before embryo transplantation, preventing the birth of defective children, and improving the survival rate of the children. And the genetic transmission of the CNV microdeletion and microduplication syndrome disease to the next generation is timely blocked. The development and progress of a human assisted reproduction technology are promoted to a certain extent.

The present invention discloses an application of microbubble-combined ultrasound intervention in preparing a system for improving receptivity of thin-type endometrium. The microbubble-combined ultrasound intervention provided for the first time can enhance expressions of IGFBP-1 and VEGF in the endometrium, improve decidualization status and blood supply of the endometrium, and increase thicknessof the thin-type endometrium. The system expands use ranges of the microbubble-combined ultrasound and at the same time also provides a new direction for improving the receptivity of the thin-type endometrium; and besides, from results of animal experiments, the microbubble-combined ultrasound intervention can increase the thickness of the endometrium, reconstructs local blood supply and glands,has a relatively good effect, provides new methods and new ideas for clinical treatment of the thin-type endometrium, thus looks forward to increase the thickness of the endometrium through intrauterine infusion of ultrasound microbubbles, improves a clinical pregnancy rate of patients with the thin-type endometrium and solves one of two key factors for successful embryo implantation.